-
Combination oral contraceptives (OCs) are the most common form of hormonal contraception used by sexually active females ages 15-19, with 56% of this group reporting ever having used OCs, and 30% reporting use at last intercourse.
-
While pills remain a popular birth control choice, more women are selecting long-acting reversible contraception (LARC), say respondents to the 2011 Contraceptive Technology Update Contraception Survey. More than 80% of respondents say they have seen an increase in LARC methods.
-
A woman comes into your office and says she wants to use an oral contraceptive (OC) for birth control. After confirming that she is a good candidate for the method, when do you start her on her first pack of pills?
-
While combined oral contraceptives (OCs) remain a leading choice for contraception, other methods are making their mark. About 38% of respondents to the 2011 Contraceptive Technology Update Contraception Survey said more than half of their patients use OCs, a drop from 2010's 42% level.
-
New labeling is being eyed regarding increased risks for blood clots for the contraceptive patch and combined oral contraceptives (COCs) containing the progestin drospirenone (DRSP) following recommendations from joint votes from two Food and Drug Administration (FDA) committees.
-
Almost 75% of respondents to the Contraceptive Technology Update 2011 Contraception Survey say they provide advance provision of emergency contraception (EC).
-
To investigate whether gonadal hormones influence cognitive function in postmenopausal women, the authors administered a comprehensive battery of neuropsychological tests on two occasions (2 years apart) to participants enrolled in the population-based, longitudinal Melbourne Women's Midlife Health Project.
-
-
It might sound obvious to a reproductive medicine specialist to say that "every cell has a sex." On the other hand, even an obstetrician-gynecologist might be surprised to know how much of a contribution sex differences make to health and disease.
-
In this issue: New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
